Oric Pharmaceuticals Investor Relations Material

Oric Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies aimed at overcoming resistance in cancer. The company is dedicated to addressing one of the most significant challenges in oncology by targeting resistance mechanisms to improve the efficacy and durability of cancer treatments. Oric's research is concentrated on three primary resistance pathways: innate resistance, acquired resistance, and bypass resistance. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.